Gómez-Sáez José-Manuel
a Researcher of CIBERDEM (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas), Endocrinology Service , Hospital Universitario de Bellvitge , Barcelona , Spain.
Expert Opin Investig Drugs. 2016 Nov;25(11):1345-1352. doi: 10.1080/13543784.2016.1242577. Epub 2016 Oct 6.
Sunitinib is an oral oxindol derivative and a potent inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor and a multitargeted tyrosine-kinase inhibitor, which has antitumor and antiangiogenic activity due to the selective inhibition that can stabilize progressive metastatic disease. The aim of this review is to expose whether the drug could be considered as a new promising therapy compared with other tyrosine-kinase inhibitors. Areas covered: In seven open-label studies carried out with sunitinb, the drug showed its anti-tumoral activity in advanced differentiated thyroid carcinoma and in medullary thyroid carcinoma. The reported objectives in advanced differentiated thyroid carcinoma, partial response ranges 13% to 55.5%, stable disease ranges 44.4% to 68%, progressive disease ranges 10% to 21% of patients, progression free survival ranges 3 to 13.3% months. In medullary thyroid carcinoma, PR ranges 0% to 55%, SD ranges 44.4% to 87.5%, PD ranges 7% to 18.8% and progression free survivalranges seven to 21 months. Expert opinion: Sunitinib has demonstrated a potent anti-tumoral activity in differentiated thyroid carcinoma and in medullary thyroid carcinoma, but the results of the open-label trials single arm are limited. Further investigations with this agent with randomized trials are warranted.
舒尼替尼是一种口服的氧化吲哚衍生物，是血管内皮生长因子受体和血小板衍生生长因子受体的强效抑制剂，也是一种多靶点酪氨酸激酶抑制剂，因其能通过选择性抑制稳定进展性转移性疾病而具有抗肿瘤和抗血管生成活性。本综述的目的是探讨与其他酪氨酸激酶抑制剂相比，该药物是否可被视为一种有前景的新疗法。涵盖领域：在用舒尼替尼进行的7项开放标签研究中，该药物在晚期分化型甲状腺癌和甲状腺髓样癌中显示出抗肿瘤活性。在晚期分化型甲状腺癌中报告的目标中，部分缓解率为13%至55.5%，疾病稳定率为44.4%至68%，疾病进展率为患者的10%至21%，无进展生存期为3至13.3个月。在甲状腺髓样癌中，部分缓解率为0%至55%，疾病稳定率为44.4%至87.5%，疾病进展率为7%至18.8%，无进展生存期为7至21个月。专家意见：舒尼替尼在分化型甲状腺癌和甲状腺髓样癌中已显示出强效抗肿瘤活性，但开放标签单臂试验的结果有限。有必要对该药物进行进一步的随机试验研究。
